key: cord-1051441-huj7f1mq authors: Pai, Menaka title: Epidemiology of VITT date: 2022-02-08 journal: Semin Hematol DOI: 10.1053/j.seminhematol.2022.02.002 sha: bca226842c11f866bdc83a7cf33a4da2277eda23 doc_id: 1051441 cord_uid: huj7f1mq Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a life-threatening syndrome of aggressive thrombosis, often profound thrombocytopenia, and frequently overt disseminated intravascular coagulation. It has been associated with two adenovirus vector COVID-19 vaccines: ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Janssen). Unlike the myriad of other conditions that cause thrombosis and thrombocytopenia, VITT has an important distinguishing feature: affected individuals have platelet-activating anti-PF4 antibodies that appear in a predictable time frame following vaccination. The reported incidence of VITT differs between jurisdictions; it is dependent on accurate ascertainment of cases and accurate estimates of the size of the vaccinated population. The incidence ranges from 1 case per 26,500 to 127,3000 first doses of ChAdOx1 nCoV-19 administered. It is estimated at 1 case per 518,181 second doses of ChAdOx1 nCoV-19 administered, and 1 case per 263,000 Ad26.COV2.S doses administered. There are no clear risk factors for VITT, including sex, age, or comorbidities. VITT is a rare event, but its considerable morbidity and mortality merit ongoing pharmacovigilance, and accurate case ascertainment. and thrombocytopenia, VITT has an important distinguishing feature: affected individuals have platelet-activating anti-PF4 antibodies that appear in a predictable time frame following vaccination. The reported incidence of VITT differs between jurisdictions; it is dependent on accurate ascertainment of cases and accurate estimates of the size of the vaccinated population. The incidence ranges from 1 case per 26, 500 to 127,3000 first doses of ChAdOx1 nCoV-19 administered. It is estimated at 1 case per 518,181 second doses of ChAdOx1 nCoV-19 administered, and 1 case per 263,000 Ad26.COV2.S doses administered. There are no clear risk factors for VITT, including sex, age, or comorbidities. VITT is a rare event, but its considerable morbidity and mortality merit ongoing pharmacovigilance, and accurate case ascertainment. Keywords vaccine, thrombosis, thrombocytopenia, epidemiology In February 2021, early reports of cases of thrombosis and thrombocytopenia began emerging from a number of European countries using the ChAdOx1 nCoV-19 (AstraZeneca, University of Oxford, and Serum Institute of India) COVID-19 vaccine. Similar cases were soon reported in Canada and Australia, and then from the United States in patients receiving the Ad26.COV2.S (Janssen) vaccine. Several terms were initially used to describe this life-threatening syndrome of aggressive thrombosis, often profound thrombocytopenia, and frequently overt disseminated intravascular coagulation (DIC); however, the term that has become most widely accepted is vaccineinduced immune thrombotic thrombocytopenia (VITT).(1) Since early 2021, there have been significant advances in developing an appropriate case definition of VITT. We also have a better understanding of the risk of this syndrome, in terms of its incidence and potential risk factors. The Brighton Collaboration is an international voluntary collaboration of scientific experts that releases standardized case definitions for vaccine adverse events, as well as reporting templates for benefit-risk assessment of vaccines. Use of the Brighton Collaboration's standardized definitions and tools allows for a structured approach to evaluating vaccine safety, across jurisdictions. The Brighton Collaboration has proposed the term -thrombosis and thrombocytopenia syndrome‖ (TTS) in their Case Definition, instead of VITT. (7) This was an intentional choice, as TTS does not imply causality or a relationship to anti-PF4 antibodies or vaccines. It is an overarching term, and includes patients with VITT as well as patients who have thrombosis and thrombocytopenia for other reasons, such as (non-VITT) disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, or cancer. It also encompasses patients with non-immune thrombosis who have mild pre-existing thrombocytopenia for various reasons (e.g., ITP, hypersplenism, hereditary causes). The advantage of a broad term like TTS is that it allows for straightforward comparative data to be collected by regulatory authorities. However, these data then need to be examined to determine what proportion represent true cases of VITTa condition that, by definition, is induced by vaccines, and for which a definitive laboratory marker (platelet-activating anti-PF4 antibodies) has been identified. The Brighton Collaboration's case definition is useful in standardizing case ascertainment and reporting of VITT; this is essential for pharmacovigilance activities, research around diagnosis and treatment, and issuing of clinical guidance to ensure individuals with VITT get appropriate and timely care. The case definition also has value because it does not require a positive anti-platelet factor 4 assay to confirm TTS; these assays can be difficult, if not impossible, to access in low resource settings. The Brighton Collaboration's case definition is challenged by the emphasis it puts on its first criterion: evidence of new thrombocytopenia with no recent exposure to heparin. This criterion is heavily weighted determining the level of certainty of a case of TTS. However there have been published report of patients who presented with thrombosis but had either normal platelet counts or very mild thrombocytopenia. (8, 9) There is also an emphasis on thrombosis as a presenting symptomeither objectively By way of analogy, it is well-recognized that in heparin-induced thrombocytopenia (HIT) a significant proportion of patients (approximately 25% to 50%) do not develop thrombosis; however the frequency of thrombosis in atypical presentations of HIT, such as -autoimmune HIT‖ that features strong heparin-independent platelet-activating properties, appears to be >95%, (14) Nevertheless, thrombosis is not a necessary criterion to diagnose HIT; patients whose platelet count fall bears a temporal relationship to preceding heparin treatment, and whose blood contains plateletactivating anti-PF4 antibodies, are widely accepted as having -HIT‖ even if a thrombotic event is never detected. It seems plausible therefore that patients who develop thrombocytopenia in the setting of platelet-activating anti-PF4 antibodies following vaccination could also be deemed to have VITT even if thrombosis is not clinically evident, and even if this may be a relatively uncommon presentation Differentiating VITT and TTS is not a purely academic exercise. TTS is a useful label to describe patients with thrombosis and thrombocytopenia after vaccination, who represent a myriad of aetiologies. VITT represents a more narrow group of patients, who have a high mortality, and require urgent, early, and specific diagnosis and treatment. The term VITT implies both causality (i.e., a vaccine) and a mechanism (i.e., immune-mediation). A recent publication by Thiele and colleagues retrospectively The denominator becomes more reliable if vaccination with the vaccine of concern is paused, allowing for an accurate estimation of who has received it. Countries with higher data quality tend to show higher estimates of the risk of VITT. Initial reports emphasized female sex and younger age as risk factors for VITT; this led several jurisdictions to restrict the use of adenoviral vector vaccines. However many of these initial observations were likely artefactual; in many countries, healthcare professionals (whose demographics skew towards younger females) were prioritized in the initial rollout of the ChAdOx1 nCoV-19 vaccine, which led to a predominance of certain demographic factors in early reports of VITT. (21) Sex Initial reports from Norway and Germany suggested female sex was a risk factor; 13 of the 16 patients in these reports were female. (17, 22) A female predominance seemed logical; heparin-induced thrombocytopenia, a related condition, tends to affect females, and immune disorders in general are more common in females. (23) However it soon became clear, as other countries began reporting cases, that the apparent female predominance simply reflected the demographics of the initial rollout of the vaccine. Canada restricted the ChAdOx1 nCoV-19 to older individuals, and preferentially gave mRNA vaccines to healthcare professionals; in three of the first cases from Canada, two were males, and all were over age 60. There does appear to be an association between the risk of VITT and younger age. The United Kingdom reports the risk of VITT after the first dose of ChAdOx1 nCoV-19 as one in 100 000 for people older than 50 years of age and one in 50 000 for those younger than 50 years of age. VITT is a rare vaccine adverse eventhowever its mortality and morbidity, and the sheer numbers of individuals who have and will receive implicated vaccines make it a serious entity that merits pharmacovigilance, and concerted efforts to raise healthcare professional and public awareness. Case ascertainment should be guided by standardized definitions, and should also take into account early and seemingly atypical presentations. Dr. Pai has provided expert witness testimony relating to non-VITT thrombocytopenic and coagulopathic disorders. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. VIPIT versus VITT: what's in a name? Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines Thrombosis After Vaccination With Messenger RNA-1273: Is This Vaccine-Induced Thrombosis and Thrombocytopenia or Thrombosis With Thrombocytopenia Syndrome? Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine Case Series of Thrombosis with Thrombocytopenia Syndrome following COVID-19 vaccination-United States Thrombosis and thrombocytopenia after HPV vaccination -Johansen --Journal of Thrombosis and Haemostasis -Wiley Online Library Updated Brighton Collaboration Case Definition for Thrombosis with Thrombocytopenia Syndrome (TTS) [Internet]. Brighton Collaboration Vaccine-induced immune thrombotic thrombocytopenia presenting with normal platelet count Venous Thromboembolism and Mild Thrombocytopenia after Vaccination Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis. Blood Adv Most cases of Thrombosis and Thrombocytopenia Syndrome (TTS) post ChAdOx-1 nCov-19 are Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) -The Lancet Regional Health -Europe Vaccine-Induced Thrombocytopenia with Severe Headache Autoimmune heparin-induced thrombocytopenia Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: Retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany -ScienceDirect Australian Government Department of Health, Therapeutic Goods Administration Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination Coronavirus vaccine -weekly summary of Yellow Card reporting Updates to the benefit/risk assessment for Janssen COVID-19 vaccines: Applying the Evidence to Recommendation Framework Risk of Vaccine-Induced Thrombotic Thrombocytopenia (VITT) following the AstraZeneca/COVISHIELD Adenovirus Vector COVID-19 Vaccines Ontario COVID-19 Science Advisory Table Vaccine-induced immune thrombotic thrombocytopenia Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis No Correlation between Anti-PF4 and Anti-SARS-CoV-2 Antibodies after ChAdOx1 nCoV-19 Vaccination Antiplatelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein